Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE)

NCT05050084 is registered in ClinicalTrials.gov with NRG Oncology as lead sponsor.

NCT NCT05050084
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05050084 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE)
Lead sponsor
NRG Oncology
Phase
Phase 3
Overall status
Active, not recruiting
Start date
December 6, 2021
Completion date
November 11, 2031
Enrollment
2,050 (estimated)
Sites
576

Conditions

As the registry lists them; a condition with its own page is linked.

prostate adenocarcinoma